|
US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US20060002935A1
(en)
*
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
|
US20130216538A1
(en)
*
|
2002-12-27 |
2013-08-22 |
Domantis Limited |
Compositions and Methods for Treating Inflammatory Disorders
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
KR100956913B1
(ko)
*
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
SI2311874T1
(sl)
|
2004-07-22 |
2017-12-29 |
Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics |
Vezavne molekule
|
|
ES2422893T3
(es)
*
|
2004-08-02 |
2013-09-16 |
Sami Labs Limited |
Composiciones y procedimientos para el tratamiento de las afecciones dermatológicas hiperproliferativas
|
|
EP1773885B1
(en)
|
2004-08-05 |
2010-04-21 |
Genentech, Inc. |
Humanized anti-cmet antagonists
|
|
EP1817430B1
(en)
*
|
2004-11-29 |
2009-09-16 |
Klinikum der Universität Regensburg |
Means and methods for detecting methylated dna
|
|
AU2005308916B2
(en)
|
2004-11-29 |
2011-07-21 |
Sequenom, Inc. |
Kits and methods for detecting methylated DNA
|
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
|
WO2006122787A1
(en)
|
2005-05-18 |
2006-11-23 |
Ablynx Nv |
Serum albumin binding proteins
|
|
US20090092593A1
(en)
*
|
2005-08-23 |
2009-04-09 |
Akira Matsumori |
Therapeutic drug for heart disease and virus disease
|
|
AR056142A1
(es)
*
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
|
PL2289909T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
|
|
US20100021473A1
(en)
*
|
2005-12-06 |
2010-01-28 |
Domantis Limited |
Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
|
|
CA2634080A1
(en)
|
2005-12-20 |
2007-06-28 |
Arana Therapeutics Limited |
Anti-inflammatory dab
|
|
CN101400703B
(zh)
|
2006-02-01 |
2013-05-08 |
赛法隆澳大利亚控股有限公司 |
结构域抗体构建体
|
|
WO2007146163A2
(en)
*
|
2006-06-09 |
2007-12-21 |
Welson Pharmaceuticals, Inc. |
Fc-fusion proteins with reduced fc-mediated effector activities
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
EP2102244A2
(en)
|
2006-12-19 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
|
CA2688433A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
|
WO2009021754A2
(en)
|
2007-08-15 |
2009-02-19 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
|
WO2009040562A1
(en)
|
2007-09-26 |
2009-04-02 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
|
EP2220120A2
(en)
|
2007-11-27 |
2010-08-25 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
AU2009235467A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Single variable domains against the Notch pathways
|
|
ES2436044T3
(es)
|
2008-05-23 |
2013-12-26 |
Ablexis, Llc |
Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos
|
|
HRP20170374T1
(hr)
|
2008-09-26 |
2017-05-05 |
Ucb Biopharma Sprl |
Biološki proizvodi
|
|
EP2210902A1
(en)
|
2009-01-14 |
2010-07-28 |
TcL Pharma |
Recombinant monovalent antibodies
|
|
CN102405236A
(zh)
|
2009-02-19 |
2012-04-04 |
葛兰素集团有限公司 |
改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
|
|
NZ595461A
(en)
|
2009-04-10 |
2013-01-25 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
EP2435477A1
(en)
*
|
2009-05-28 |
2012-04-04 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
ES2643034T3
(es)
|
2009-06-05 |
2017-11-21 |
Ablynx N.V. |
Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
|
|
EP2453920A2
(en)
|
2009-07-16 |
2012-05-23 |
Glaxo Group Limited |
Antagonists, uses & methods for partially inhibiting tnfr1
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
BR112012010114A2
(pt)
|
2009-10-27 |
2017-08-08 |
Glaxo Group Ltd |
domínio variável único de imunoglobulina, ligante multiespecífico, antagonista, uso do antagonista, método para tratamento e/ou profilaxia de uma condição inflamatória em um paciente, ácido nucleico, vetor, e, célula hospedeira.
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
US8754287B2
(en)
|
2009-12-10 |
2014-06-17 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
EP2513145B1
(en)
|
2009-12-14 |
2018-01-24 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
SI2501817T2
(sl)
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
EP2536764B1
(en)
|
2010-02-18 |
2018-07-04 |
OSE Immunotherapeutics |
Anti-cd28 humanized antibodies
|
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
|
ES2684475T3
(es)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteínas que se unen a beta amiloide
|
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
|
US8911728B2
(en)
|
2010-05-21 |
2014-12-16 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins
|
|
SG10201912639SA
(en)
*
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
|
EA202092589A3
(ru)
|
2010-11-08 |
2021-06-30 |
Аблинкс Н.В. |
Cxcr2-связывающие полипептиды
|
|
CA2827170A1
(en)
|
2011-02-11 |
2012-08-16 |
David M. Hilbert |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
EP2699597B1
(en)
|
2011-04-21 |
2016-06-01 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
RU2013155695A
(ru)
|
2011-06-30 |
2015-08-10 |
Дженентек, Инк. |
Препараты антител против с-мет
|
|
RS59728B1
(sr)
|
2011-08-05 |
2020-02-28 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lanca
|
|
RU2664181C2
(ru)
|
2011-12-20 |
2018-08-15 |
Регенерон Фармасьютикалз, Инк. |
Мыши с гуманизированной легкой цепью
|
|
WO2013106572A1
(en)
*
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
KR102276752B1
(ko)
*
|
2014-03-21 |
2021-07-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
KR20250099289A
(ko)
|
2014-05-16 |
2025-07-01 |
아블린쓰 엔.브이. |
개선된 면역글로불린 가변 도메인
|
|
PL3248986T3
(pl)
|
2014-05-16 |
2022-05-16 |
Ablynx Nv |
Domeny zmienne immunoglobuliny
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
US10584175B2
(en)
|
2014-10-23 |
2020-03-10 |
La Trobe University |
FN14-binding proteins and uses thereof
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
RS61907B1
(sr)
|
2015-04-06 |
2021-06-30 |
Subdomain Llc |
Polipeptidi koji sadrže de novo vezujući domen i njihova primena
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US10266589B2
(en)
|
2015-07-29 |
2019-04-23 |
Allergan, Inc. |
Heavy chain only antibodies to ANG-2
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
WO2017030909A1
(en)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
HK1254635A1
(zh)
|
2015-12-17 |
2019-07-26 |
Novartis Ag |
C-met抑制剂与pd-1抗体分子的组合及其用途
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
MY209117A
(en)
|
2016-04-15 |
2025-06-23 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
KR102460040B1
(ko)
|
2016-04-27 |
2022-11-01 |
애브비 인코포레이티드 |
항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
BR112019001570A2
(pt)
|
2016-07-28 |
2019-07-09 |
Novartis Ag |
terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
|
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CA3043515A1
(en)
|
2016-11-16 |
2018-05-24 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN118307674A
(zh)
|
2017-06-22 |
2024-07-09 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
CN111670198B
(zh)
|
2017-09-11 |
2023-12-15 |
莫纳什大学 |
人凝血酶受体par4的结合蛋白
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
AU2018369639C1
(en)
|
2017-11-14 |
2025-04-03 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
TW201922291A
(zh)
|
2017-11-16 |
2019-06-16 |
瑞士商諾華公司 |
組合療法
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CN112654394B
(zh)
|
2018-06-19 |
2025-07-11 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
MX2021007391A
(es)
|
2018-12-20 |
2021-09-23 |
Novartis Ag |
Regimenes de baja dosis extendida para inhibidores de mdm2.
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
EP3927828A4
(en)
|
2019-02-21 |
2023-02-01 |
Enosi Life Sciences Corp. |
ANTIBODIES AND ENONOMERS
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
KR20220029546A
(ko)
|
2019-03-29 |
2022-03-08 |
아타르가, 엘엘씨 |
항 fgf23 항체
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
|
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
PH12023550015A1
(en)
|
2020-07-16 |
2024-03-11 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4204094A1
(en)
|
2020-08-27 |
2023-07-05 |
Enosi Therapeutics Corporation |
Methods and compositions to treat autoimmune diseases and cancer
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Ｆｃ変異体
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CA3209052A1
(en)
|
2021-02-19 |
2022-08-25 |
Rafael Cristian CASELLAS |
Single domain antibodies that neutralize sars-cov-2
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
EP4605077A1
(en)
|
2022-10-18 |
2025-08-27 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2025049818A1
(en)
|
2023-08-29 |
2025-03-06 |
Enosi Therapeutics Corporation |
Tnfr1 antagonists lacking agonist activity and uses thereof
|
|
AR134267A1
(es)
|
2023-11-08 |
2025-12-17 |
Sanofi Sa |
Degradador lisosómico basado en cd25 y usos del mismo
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US12357539B1
(en)
|
2024-05-16 |
2025-07-15 |
Genzyme Corporation |
Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026052756A1
(en)
|
2024-09-05 |
2026-03-12 |
Ablynx Nv |
Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
|
|
WO2026058155A1
(en)
|
2024-09-11 |
2026-03-19 |
Novartis Ag |
Antibodies targeting il-31
|
|
US12357538B1
(en)
|
2024-11-25 |
2025-07-15 |
Genzyme Corporation |
Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
|
|
US12377023B1
(en)
|
2024-12-02 |
2025-08-05 |
Genzyme Corporation |
Fluid transfer device
|
|
US12539367B1
(en)
|
2025-02-26 |
2026-02-03 |
Genzyme Corporation |
Medicament delivery device
|
|
US12434008B1
(en)
|
2025-02-26 |
2025-10-07 |
Genzyme Corporation |
Lock ring for a medicament delivery device
|
|
US12420017B1
(en)
|
2025-02-26 |
2025-09-23 |
Genzyme Corporation |
Damping device for a medicament delivery device
|
|
US12465697B1
(en)
|
2025-02-26 |
2025-11-11 |
Genzyme Corporation |
Medicament delivery device
|